Perform Another (Advanced) Search

1.  Newly Approved Drug Therapies (756) Kineret, Amgen,
...not limited to) the following: • • Injection site reaction • Infection • Headache • Nausea Mechanism of Action Kineret (anakinra) is a direct and selective blocker of interleukin-1 (IL-1) that works by inhibiting ...
View Page

2.  Study Posting (2665) Trial #154656, Rheumatoid Arthritis, Kalamazoo, MI
...within 3 months or within 5 half lives prior to baseline except for etanercept or anakinra for which there is a one month washout prior to baseline (DC’d biological must ...
View Page

3.  Study Posting (5231) Trial #143761, Rheumatoid Arthritis, Various Cities, Romania
...or previously had received a biologic therapy with an inhibitor of TNF, rituximab, abatacept or anakinra at an approved label dose Key exclusion criteria • Uncontrolled or poorly controlled hypertension • Other autoimmune ...
View Page

4.  Study Posting (5231) Trial #143760, Rheumatoid Arthritis, Cluj, Romania
...or previously had received a biologic therapy with an inhibitor of TNF, rituximab, abatacept or anakinra at an approved label dose Key exclusion criteria • Uncontrolled or poorly controlled hypertension • Other autoimmune ...
View Page

5.  Study Posting (5231) Trial #143759, Rheumatoid Arthritis, Various Cities, Poland
...or previously had received a biologic therapy with an inhibitor of TNF, rituximab, abatacept or anakinra at an approved label dose Key exclusion criteria • Uncontrolled or poorly controlled hypertension • Other autoimmune ...
View Page

6.  Study Posting (5231) Trial #143758, Rheumatoid Arthritis, Various Cities, Poland
...or previously had received a biologic therapy with an inhibitor of TNF, rituximab, abatacept or anakinra at an approved label dose Key exclusion criteria • Uncontrolled or poorly controlled hypertension • Other autoimmune ...
View Page

7.  Study Posting (5231) Trial #143757, Rheumatoid Arthritis, Various Cities, Poland
...or previously had received a biologic therapy with an inhibitor of TNF, rituximab, abatacept or anakinra at an approved label dose Key exclusion criteria • Uncontrolled or poorly controlled hypertension • Other autoimmune ...
View Page

8.  Study Posting (5231) Trial #143756, Rheumatoid Arthritis, Various Cities, Poland
...or previously had received a biologic therapy with an inhibitor of TNF, rituximab, abatacept or anakinra at an approved label dose Key exclusion criteria • Uncontrolled or poorly controlled hypertension • Other autoimmune ...
View Page

9.  Study Posting (5231) Trial #143755, Rheumatoid Arthritis, Various Cities, Poland
...or previously had received a biologic therapy with an inhibitor of TNF, rituximab, abatacept or anakinra at an approved label dose Key exclusion criteria • Uncontrolled or poorly controlled hypertension • Other autoimmune ...
View Page

10.  Study Posting (5231) Trial #143754, Rheumatoid Arthritis, Various Cities, Poland
...or previously had received a biologic therapy with an inhibitor of TNF, rituximab, abatacept or anakinra at an approved label dose Key exclusion criteria • Uncontrolled or poorly controlled hypertension • Other autoimmune ...
View Page

11.  Study Posting (5231) Trial #143751, Rheumatoid Arthritis, Lima, Peru
...or previously had received a biologic therapy with an inhibitor of TNF, rituximab, abatacept or anakinra at an approved label dose Key exclusion criteria • Uncontrolled or poorly controlled hypertension • Other autoimmune ...
View Page

12.  Study Posting (5231) Trial #143750, Rheumatoid Arthritis, Lima, Peru
...or previously had received a biologic therapy with an inhibitor of TNF, rituximab, abatacept or anakinra at an approved label dose Key exclusion criteria • Uncontrolled or poorly controlled hypertension • Other autoimmune ...
View Page

13.  Study Posting (5231) Trial #143753, Rheumatoid Arthritis, Lima, Peru
...or previously had received a biologic therapy with an inhibitor of TNF, rituximab, abatacept or anakinra at an approved label dose Key exclusion criteria • Uncontrolled or poorly controlled hypertension • Other autoimmune ...
View Page

14.  Study Posting (5231) Trial #143752, Rheumatoid Arthritis, Callao, Peru
...or previously had received a biologic therapy with an inhibitor of TNF, rituximab, abatacept or anakinra at an approved label dose Key exclusion criteria • Uncontrolled or poorly controlled hypertension • Other autoimmune ...
View Page

15.  Study Posting (5231) Trial #143749, Rheumatoid Arthritis, Various Cities, Mexico
...or previously had received a biologic therapy with an inhibitor of TNF, rituximab, abatacept or anakinra at an approved label dose Key exclusion criteria • Uncontrolled or poorly controlled hypertension • Other autoimmune ...
View Page

16.  Study Posting (5231) Trial #143748, Rheumatoid Arthritis, Morelos, Mexico
...or previously had received a biologic therapy with an inhibitor of TNF, rituximab, abatacept or anakinra at an approved label dose Key exclusion criteria • Uncontrolled or poorly controlled hypertension • Other autoimmune ...
View Page

17.  Study Posting (5231) Trial #143747, Rheumatoid Arthritis, Morelos, Mexico
...or previously had received a biologic therapy with an inhibitor of TNF, rituximab, abatacept or anakinra at an approved label dose Key exclusion criteria • Uncontrolled or poorly controlled hypertension • Other autoimmune ...
View Page

18.  Study Posting (5231) Trial #143746, Rheumatoid Arthritis, Mexico City, Mexico
...or previously had received a biologic therapy with an inhibitor of TNF, rituximab, abatacept or anakinra at an approved label dose Key exclusion criteria • Uncontrolled or poorly controlled hypertension • Other autoimmune ...
View Page

19.  Study Posting (5231) Trial #143745, Rheumatoid Arthritis, Guanajuato, Mexico
...or previously had received a biologic therapy with an inhibitor of TNF, rituximab, abatacept or anakinra at an approved label dose Key exclusion criteria • Uncontrolled or poorly controlled hypertension • Other autoimmune ...
View Page

20.  Study Posting (5231) Trial #143744, Rheumatoid Arthritis, Various Cities, Italy
...or previously had received a biologic therapy with an inhibitor of TNF, rituximab, abatacept or anakinra at an approved label dose Key exclusion criteria • Uncontrolled or poorly controlled hypertension • Other autoimmune ...
View Page